[Molecule targeted therapy for hematological malignancies].
Over the past 20 years, there has been a marked increase in our knowledge of the molecular mechanisms of human hematological malignancies. The development of mechanism-based therapy is expected to extend the frontiers of chemotherapy. All-trans retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL), initially established as differentiation therapy, has been recognized to target PML-RAR alpha protein, an APL-specific chimeric transcriptional factor, and to modulate the function. Recently, encouraging results have emerged in the treatment of chronic myeloid leukemia with a tyrosine-kinase inhibitor. In addition to the oncoprotein-targeted therapy, the clinical effectiveness of humanized monoclonal antibodies to differentiation antigens has been recognized. Molecule-targeted therapy is reviewed herein.
Naoe
T
T
Dept. of Infectious Diseases, Nagoya University School of Medicine.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D014212:Tretinoin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D014212:Tretinoin; D011505:Protein-Tyrosine Kinases